Spanish drugmaker Almirall has agreed to pay $6.6 million to
resolve claims that its U.S. unit paid kickbacks to incentivize
doctors to prescribe its dermatology products, the U.S. Justice
Department and lawyers for a whistleblower said on Wednesday.
* SAID ON WEDNESDAY THAT NATIONAL INSTITUTE FOR HEALTH AND
EXCELLENCE (NICE) IN UK HAD PUBLISHED ITS FINAL RECOMMENDATION
FOR ILUMETRI (TILDRAKIZUMAB) AS A COST-EFFECTIVE OPTION TO TREAT
MODERATE-TO-SEVERE PLAQUE PSORIASIS